U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C11H17NO
Molecular Weight 179.2592
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEXILETINE

SMILES

Cc1cccc(C)c1OCC(C)N

InChI

InChIKey=VLPIATFUUWWMKC-UHFFFAOYSA-N
InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C11H17NO
Molecular Weight 179.2592
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Mexiletine is a non-selective voltage-gated sodium channel blocker which belongs to the Class IB anti-arrhythmic group of medicines. It is used to treat heart arrhythmias. Mexiletine is also used to treat refractory pain and muscle stiffness resulting in myotonic dystrophy or myotonia congenita. Mexiletine was approved for commercial use in 1985 under the brand name Mexitil, but most marketing efforts have since been discontinued. There has been a continued effort to identify other therapeutic use cases and a number of clinical trials have been conducted including ALS and chronic pain from amputation.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MEXITIL

Approved Use

Mexiletine hydrochloride capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.

Launch Date

504748800000
Primary
MEXITIL

Approved Use

Mexiletine hydrochloride capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias.

Launch Date

504748800000
Primary
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.21 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.2 μg/mL
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.59 μg/mL
100 mg 3 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.35 μg/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.46 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.45 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.81 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.96 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22 μg × h/mL
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.7 μg × h/mL
100 mg 3 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.8 μg × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.7 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.76 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.3 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.4 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9.9 h
200 mg 3 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.1 h
100 mg 3 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10.8 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
10 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.1 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
40%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MEXILETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
500 mg single, intramuscular
Highest studied dose
Dose: 500 mg
Route: intramuscular
Route: single
Dose: 500 mg
Sources:
unhealthy, 55-78
Health Status: unhealthy
Age Group: 55-78
Sex: M+F
Sources:
400 mg 3 times / day multiple, oral
MTD
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
unhealthy, 55.5
Health Status: unhealthy
Age Group: 55.5
Sex: M+F
Sources:
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Migraine, Gastrointestinal discomfort...
AEs leading to
discontinuation/dose reduction:
Migraine (1.7%)
Gastrointestinal discomfort (1.7%)
Sources:
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (2.6%)
Sources:
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Disc. AE: Tachycardia...
AEs leading to
discontinuation/dose reduction:
Tachycardia (severe, 4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal discomfort 1.7%
Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Migraine 1.7%
Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Diarrhea 2.6%
Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Tachycardia severe, 4%
Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
major
minor
yes (co-administration study)
Comment: coadminitration with fluvoxamine decreased mexiletine clearance by 38%
Page: 1, 2
Tox targets
PubMed

PubMed

TitleDatePubMed
Mexiletine in the treatment of ventricular arrhythmias.
1980
Torsades de pointes as a manifestation of mexiletine toxicity.
1980 Dec
New drugs for treating cardiac arrhythmias.
1981 Jan
[Mexiletine in the treatment of lidocaine-resistant ventricular tachycardia. Preliminary results].
1982
Mexiletine in refractory ventricular arrhythmias.
1983 Dec
Drug interactions with amiodarone.
1983 Oct
International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group.
1984 Dec
Hemodynamic effects of mexiletine.
1984 May
Facilitation of ventricular tachyarrhythmia induction by isoproterenol.
1984 Oct 1
Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies.
1984 Sep
Inhibition of sympathetic nervous system by mexiletine, an antiarrhythmic agent, and its antagonism against ouabain.
1985
Mexiletine: long-term follow-up of a patient with prolonged QT interval and quinidine-induced torsades de pointes.
1985 Feb
[Anti-arrhythmic efficacy of the amiodarone-mexiletine combination in the treatment of resistant complex ventricular arrhythmias].
1986 May
Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.
1987 Dec 1
[2 cases of lidocaine-resistant ventricular tachycardia treated with i.v. mexiletine during complicated acute myocardial infarct].
1987 Nov 30
General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
1988 Oct
Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts.
1989 Jul
Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents.
1989 Jun
Congestive heart failure induced by six of the newer antiarrhythmic drugs.
1989 Nov 1
Long-term effect of mexiletine on left ventricular function and relation to suppression of ventricular arrhythmia.
1990 Nov 15
Mexiletine-associated left ventricular dysfunction: a case study.
1991 Jun
Neurotoxicity of lidocaine combined with mexiletine.
1993 Dec
Mexiletine-induced severe skin eruption, fever, eosinophilia, atypical lymphocytosis, and liver dysfunction.
1997 Oct
Effects of mexiletine on algogenic mediator-induced nociceptive responses in mice.
1999 Jul-Aug
Lack of stereoselectivity for the antiallodynic effect of mexiletine in spinally injured rats.
2000
Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome.
2000 Aug
Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: a double-blind, placebo-controlled, crossover study.
2000 Sep-Oct
Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study.
2000 Sep-Oct
Schwartz-Jampel syndrome: report of one case.
2002 Jul-Aug
Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome.
2003 Aug 22
Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
2004 Feb 1
Antinociceptive effects of sodium channel-blocking agents on acute pain in mice.
2004 Jun
Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells.
2005 Dec 28
Effect of mexiletine on vincristine-induced painful neuropathy in mice.
2006 Apr 24
Digoxin and mexiletine sensitivity in a Collie with the MDR1 mutation.
2006 Mar-Apr
Pharmacological characterization and gene expression profiling of an L5/L6 spinal nerve ligation model for neuropathic pain in mice.
2008 May 2
Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current.
2009 Jun
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.
2009 Jun 15
Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain.
2010 May
Bisphenol A binds to the local anesthetic receptor site to block the human cardiac sodium channel.
2012
Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.
2012 Sep
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
2013 Dec
Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
2015 Nov
Patents

Sample Use Guides

Mexiletine dosage must be individualized on the basis of response and tolerance. Administration with food is recommended. Initiate Mexiletine hydrochloride therapy with 200 mg every 8 hours when rapid control of arrhythmia is not essential. A minimum of two to three days between dose adjustments is recommended. The dose may be adjusted up or down in 50 or 100 mg increments. Most patients achieve satisfactory control with between 200 - 300 mg every 8 hours.The total daily dose should not exceed 400 mg.
Route of Administration: Oral
HEK293 cells stably expressing human homolog of human Nav1.5 and human Nav1.7 channels were maintained under standard tissue culture conditions (5% CO2; 37°C) in Dulbecco’s modified Eagle’s medium and F-12 medium mixture at 1:1 supplemented with 10% fetal bovine serum under selection of antibiotic G418 with a concentration of 500 μg/mL. Cells were passaged every three days with 0.25% Trypsin-EDTA. Whole-cell recordings were performed 18–24 h after plating at room temperature. Whole-cell patch-clamp recordings were conducted at room temperature (22–25°C) using an EPC-10 USB amplifier. The pipette solution contained (in mM): 140 CsF, 10 NaCl, 1 EGTA, and 10 HEPES; pH 7.3 with CsOH. The bath solution for recording contained (in mM): 140 NaCl, 3 KCl, 10 HEPES, 1 MgCl2, 1 CaCl2; pH 7.3 with NaOH. Mexiletine was diluted in bath solution to the desired concentration. Bath application of 0.3 mM mexiletine resulted in a reduction of Nav1.5 or Nav1.7 currents, while V1/2 values were not significantly shifted for even up to 1.0 mM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:34:11 UTC 2021
Edited
by admin
on Sat Jun 26 01:34:11 UTC 2021
Record UNII
1U511HHV4Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEXILETINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
MEXILETINE [MI]
Common Name English
DL-MEXILETINE
Common Name English
(RS)-MEXILETINE
Common Name English
MEXILETINE [WHO-DD]
Common Name English
1-METHYL-2-(2,6-XYLYLOXY)ETHYLAMINE
Systematic Name English
(+/-)-MEXILETINE
Common Name English
(+/-)-2-AMINO-1-(2',6'-DIMETHYLPHENOXY)PROPANE
Common Name English
1-(2,6-DIMETHYLPHENOXY)-2-PROPANAMINE
Systematic Name English
MEXILETINE [VANDF]
Common Name English
1-(2',6'-DIMETHYLPHENOXY)-2-AMINOPROPANE
Common Name English
ETHYLAMINE, 1-METHYL-2-(2,6-XYLYLOXY)-
Systematic Name English
MEXILETINE [INN]
Common Name English
2-PROPANAMINE, 1-(2,6-DIMETHYLPHENOXY)-
Systematic Name English
(2-((2,6-DIMETHYLPHENYL)OXY)-1-METHYLETHYL)AMINE
Systematic Name English
2-AMINO-1-(2,6-DIMETHYLPHENOXY)PROPANE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 728219
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
WHO-ATC C01BB02
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
NCI_THESAURUS C93038
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
NCI_THESAURUS C47793
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
FDA ORPHAN DRUG 314410
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
WHO-VATC QC01BB02
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
NDF-RT N0000175426
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
Code System Code Type Description
WIKIPEDIA
MEXILETINE
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
MESH
D008801
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
PUBCHEM
4178
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
FDA UNII
1U511HHV4Z
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
MERCK INDEX
M7518
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY Merck Index
CAS
31828-71-4
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
LACTMED
Mexiletine
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
DRUG BANK
DB00379
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
CAS
61079-93-4
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
SUPERSEDED
DRUG CENTRAL
1794
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
ChEMBL
CHEMBL558
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
EPA CompTox
31828-71-4
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
CAS
128942-27-8
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
SUPERSEDED
NCI_THESAURUS
C62047
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
CAS
718619-78-4
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
SUPERSEDED
RXCUI
6926
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY RxNorm
INN
3262
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
IUPHAR
2629
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
EVMPD
SUB08931MIG
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
ECHA (EC/EINECS)
250-825-7
Created by admin on Sat Jun 26 01:34:12 UTC 2021 , Edited by admin on Sat Jun 26 01:34:12 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC